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Abstract: 12 
This work aimed to design low-melting pressure sensitive adhesives and demonstrate the feasibility 13 
of the preparation of (trans)dermal patches by hot-melt ram extrusion printing. This approach allows 14 
defining both the geometry of (trans)dermal patch and the drug strength easily according to patient 15 
needs. The preparation steps are the mixing of a poly-ammonium methacrylate polymer (i.e. Eudragit 16 
RL and RS) with a suitable amount of plasticizer (triacetin or tributyl citrate) and the drug (ketoprofen 17 
or nicotine); the melting in the ram extruder and the printing on the backing layer foil. The 18 
formulations were characterized in terms of rheological and adhesive properties, in vitro drug release 19 
and skin permeation profiles.  20 
The (trans)dermal patches made of Eudragit RL or Eudragit RS plasticized with the 40% triacetin 21 
could be printed at 90°C giving formulations with suitable adhesive properties and which did not 22 
exhibit cold flow after 1 month of storage at 40°C. Furthermore, the overall results showed that the 23 
performances of printed (trans)dermal patches overlapped those made by solvent casting, suggesting 24 
that the proposed solvent-free technology can be useful to treat cutaneous pathologies when the 25 
availability of (trans)dermal patches with a size and a shape that perfectly fit with the skin area 26 
affected by the disease improves the safety of the pharmacological treatment. 27 
 28 
Keywords  29 
Transdermal patches, Pressure-sensitive adhesive, Eudragit RL, Eudragit RS, Hot-melt extrusion, 30 
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1 Introduction 33 
 34 
(Trans)dermal patches are well-known pharmaceutical preparations designed to be applied onto the 35 
skin surface for different purposes that range from the treatment of cutaneous pathologies to obtain a 36 
systemic effect (Cilurzo et al., 2014a). Independently of the final goal, the basic design of a 37 
(trans)dermal patch includes a backing layer, which protects the formulation from the outer 38 
environment, an adhesive matrix, which contains the drug and controls its release, and a protective 39 
foil, which is peeled out before the application of (trans)dermal patch (Wokovich et al., 2010). 40 
Usually, the adhesive matrices are made of soft thermoplastic polymeric materials able to adhere on 41 
the skin surface by simple contact under light pressure and to be peeled out without any residue. They 42 
are defined as pressure-sensitive adhesives (PSA) and can be directly synthesized for this purpose or 43 
compounded starting from pharmaceutical grade excipients (Cilurzo et al., 2008).  44 
In particular, PSA used for the development of drug-loaded (trans)dermal patches by casting 45 
techniques are available on the market or compounded as water or organic solvent dispersions 46 
(Cilurzo et al., 2014b). Alternatively, hot-melt technologies could be applied since they allow a 47 
cheaper production of (trans)dermal patches (Wilson et al., 2012). Usually, the basic approach to 48 
produce a hot-melt PSA consists in the preparation of a blend in the hot mixer, in the transfer of the 49 
obtained PSA in suitable containers and its cooling. Afterwards, the required PSA amount is 50 
deposited in a heating container and, when melted, pumped onto the coater unit, which laminates the 51 
PSA on the release liner at the desired thickness. This approach is widely used in the production of 52 
medical devices, but it has been scantly investigated in the pharmaceutical field even if hot melt PSA 53 
could open new opportunities from both a formulation and preparation point of view. Then, the PSA 54 
laminated is associated with backing layer and cut to obtain the final shape and size of the 55 
(trans)dermal patch. Both hot-melt extrusion and solvent casting are semi-continuous manufacturing 56 
processes and, therefore, unsuitable either for scaling down the batch size or the personalization of 57 
the dose. 58 
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Consequently, when the market shares of a (trans)dermal patch are too low to ensure the economic 59 
sustainability of the manufacturing process, the access to therapies is jeopardized. In this case, the 60 
availability of a system suitable for the preparation of very small batches could be useful for the 61 
specific patient need. As an example, the production of scopolamine transdermal patches, which had 62 
been indicated for the treatment of motion sickness, was interrupted in the last years. This decision 63 
of the manufacturer has a substantial impact on patients affected by amyotrophic lateral sclerosis, 64 
who used the scopolamine transdermal patches as off-label treatment for managing the sialorrhea 65 
(Garuti et al., 2019). 66 
The conventional 3D printing technologies cannot be applied to the preparation of (trans)dermal 67 
patches, since the pressure-sensitive adhesives are very soft and sticky and cannot be used for the 68 
production of pre-made filaments such those used for fused-deposition modelling (FMD) 3D printing. 69 
Only a few pieces of evidence on self-adhesive nanofiber networks have been reported (Shi et al., 70 
2014). 71 
This work explores the possibility to print of very small batch of (trans)dermal patches compatible 72 
with the extemporaneous preparation for specific patients. To demonstrate the feasibility of such a 73 
process we investigated the critical aspects related to the application of printing a melted PSA with a 74 
specific geometry on the backing layer of (trans)dermal patch. PSA made of Eudragit RL or RS, 75 
suitably plasticized by triacetin (TRI) or tributyl citrate (TBC), were used. These materials were 76 
selected since it was already demonstrated that the rheological properties of highly plasticized 77 
Eudragit RL are suitable for the preparation of PSA (Quaroni et al., 2018). Indeed, during the bonding 78 
phase (tack), these materials behave like a viscous liquid to favour its spreading onto the skin and to 79 
form good molecular contact under a lightly applied pressure. Conversely, during the debonding 80 
process from the skin (peel), the adhesive should behave like a cohesive solid to ensure complete 81 
removal without leaving any residue (O’Connor and Willenbacher, 2004). Furthermore, a 82 
(trans)dermal patch should remain attached to the skin for the entire treatment period, without any 83 
overspreading of the adhesive matrix beyond the boundaries. Therefore, it should also be highly 84 
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dissipative and lightly physically or chemically crosslinked to resist the applied stress once the bond 85 
is formed. 86 
Keeping in mind these features, the formulation space was investigated by using different 87 
copolymers’ ratio blended with different amounts of the selected plasticizers and their impact on the 88 
adhesive properties of (trans)dermal patch was also checked. Then, the suitability of the selected PSA 89 
for the preparation of (trans)dermal patches was tested by loading ketoprofen (KP) and nicotine (NT) 90 
and comparing their performances with those of analogous (trans)dermal patches prepared by casting 91 
(Quaroni et al., 2018).  92 
The printing was performed according to a protocol already described for the preparation of 93 
orodispersible films (Musazzi et al., 2018b). Briefly, the preparation procedure is simple and consists 94 
in wetting the powders (i.e. the drug and the copolymer) with the plasticizer, loading the mixture in 95 
the printer and printing the melt directly on the backing layer. Afterwards, the (trans)dermal patches 96 
were coupled with the release liner and sealed in an airtight bag. 97 
 98 
2 Materials and methods 99 
 100 
2.1 Materials 101 
Poly-(ethylacrylate-co-methylmethacrylate-co-trimethylammonioethylmethacrylate chloride), trade 102 
with the name Eudragit® RL PO (EuRL) and Eudragit® RS PO (EuRS), with a molar ratio of 1:2:0.2 103 
and 1:2:0.1 respectively, were kindly donated by Rofarma Italia (I). Tributyl citrate (TBC) was 104 
supplied by Morflex (US), whereas triacetin (TRI) and NT were purchased from Sigma Aldrich 105 
(Milan, I). KP was purchased form Farmalabor (I). The release liner and the backing layers tested 106 
were kindly donated by Bouty S.p.A. (I). All solvents were of analytical grade unless specified. 107 
 108 
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2.2 Preparation of (trans)dermal patch 109 
The mixtures were obtained by mixing the accurately weighted amount of each component in a mortar 110 
according to the composition reported in Table 1 and Table 2. The final weight of each mixture was 111 
about 10 g. 112 
The mixture was immediately transferred in the ram extrusion apparatus previously described 113 
(Musazzi et al., 2018b), melted and printed at 90°C through a 0.7-mm needle. The printer was 114 
designed modifying a Cartesian FDM 3D printer (Futura Group Srl, Italy), substituting the FDM 115 
apparatus with a home-made ram extrusion system. The distance from the needle tip to the surface of 116 
the backing layer was fixed at 0.3 mm to permit a suitable deposition of the melted blend, in a unique 117 
layer, and to obtain an adhesive matrix with a thickness around 50-70 μm. The speeds of the mobile 118 
plate and the extruder ram were set at 12 mm/s and 10 mm/s, respectively. Finally, the filling angle 119 
was set at 135° to the X-axis of the baking layer. 120 
The melted materials extruded through the die was deposited on the 20  20 cm backing layer foil 121 
fixed in the Cartesian plate of the printer. The dimension and number of (trans)dermal patches per 122 
each print were set up by 3D builder® (Microsoft, US) and converted in G-code. Afterwards, the 123 
(trans)dermal patches were matched with a siliconized polyethene film sealed in the primary 124 
packaging and stored until use without further manipulations. 125 
 126 
2.3 Rheological tests 127 
The polymeric blends were prepared according to the procedure reported above. The sample was 128 
printed on a release liner having both the surface coated with a different layer of silicon and then 129 
covered with the same material. Afterwards, the sandwich was pressed to smooth the surface. The 130 
rheological properties of the formulations were assessed and reported in Table 1. The assays were 131 
conducted at 21 ± 0.2°C using a Physica MCR 302 rheometer (Anton Paar GmbH, A) with a cone-132 
plate geometry of 1° incline, 50 mm diameter. Minimum plate gap was set at 100 µm. Before the 133 
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analyses, a strain test was performed to determine the linear viscoelastic range of the samples: after 134 
the test, shear strain for the experiments was set at 5%. 135 
Frequency sweep experiments were performed, going from 0.01 rad/s to 100 rad/s, collecting 16 136 
points in the range chosen, with logarithmic progression. The data were analysed as previously 137 
described (Quaroni et. al, 2018). The complex viscosity (η*) determined at 1.5 Hz, and the crossover 138 
of G’/G” were determined as descriptors of the rheological pattern of the prepared PSA. In particular, 139 
the η*, calculated according to the Eq. 1, was used to predict the steady shear viscosity according to 140 
the Cox-Merz rule, which states that the complex viscosity as a function of frequency is equivalent 141 
to the steady shear viscosity as a function of shear rate (Hicks et al. 2015): 142 
𝜂∗ =
𝐺∗

            (1) 143 
where G* is the complex modulus at the established angular frequency (). 144 
 145 
2.4 Thickness of (trans)dermal patch 146 
The film thickness was measured by using a micrometer MI 1000 µm (ChemInstruments, US). The 147 
results were expressed as the mean ± standard deviation of five specimens for each formulation. 148 
 149 
2.5 Optical microscopy 150 
The overall morphology, the appearance of the printed patches (including crystal formation) were 151 
evaluated by optical microscopy with a stereomicroscope (Nikon, I). Micrographs were acquired at 152 
10× magnification with a digital camera of 3.1 Mpx (CCD 3, ToupView, ToupTek, China). 153 
 154 
2.6 Adhesive properties determination 155 
The adhesive and cohesive properties of the printed (trans)dermal patches were tested applying 156 
standard procedures generally used for the characterization of (trans)dermal patches: cold flow, probe 157 
tack test, shear adhesion test and peel adhesion 180° test (Cilurzo et al., 2012; Quaroni et al., 2018). 158 
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Cold flow – The cold flow is one of the possible quality defects of (trans)dermal patches and 159 
represents the migration of a PSA outside the edge of the backing layer during the storage. This 160 
phenomenon can be observed when the matrix of (trans)dermal patch has a significant viscous-like 161 
behaviour to flow between the backing layer and release liner. The cold flow was evaluated on 162 
samples of 25 x 50 mm after a storage period of 1 month at room temperature (RT) or 40 ± 1°C. The 163 
sample complied with the test when the PSA was not visually detectable outside the backing layer. 164 
When occurring, the extent of cold flow was expressed as the maximum migration of the adhesive in 165 
millimetre on the release liner. It was measured putting the sample, which was in any case almost 166 
transparent, on a graph paper. 167 
The analysis was performed in triplicate. If the cold flow was observed, the formulation was 168 
discarded. 169 
 170 
Probe tack test – The tack adhesion test reveals the force of debonding the PSA matrix from a surface 171 
after a short contact time and applying light pressure. It is relevant for (trans)dermal patch since it 172 
allows to estimate the initial bonding of a PSA onto the application site. Briefly, (trans)dermal patches 173 
of 25 x 60 mm were printed from each formulation and stored at 25 ± 1°C for two weeks to assure 174 
the stabilization of the adhesive matrix (Quaroni et al., 2018). The probe tack test was performed 175 
according to a standard internal procedure using a tensile testing machine equipped with a 50 N cell 176 
(Instron 5965, ITW Test and Measurement Italia S.r.l., I). A strip of double-coated tape (TESA, D) 177 
having the same size of the plaster specimen was applied between the flat bottom plate of the tensile 178 
testing machine and the backing layer of the specimen. The release liner of (trans)dermal patch was 179 
then removed. The flat stainless-steel probe (diameter: 5 mm) was placed ∼0.05 mm above the 180 
adhesive matrix. The probe was then lowered onto the adhesive surface, and a constant force of 0.05 N 181 
was applied onto the sample for 5 s and, finally, the probe was removed at the debonding rate of 182 
0.1 mm/s. The absence of PSA residues on the probe surface (adhesive failure) was visually 183 
determined. The whole force-distance curve (compression and traction) was recorded. The area under 184 
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the curve force vs probe displacement was assumed as the work of separation (W). The tack stress 185 
(σmax) values for each experiment were calculated as the maximum traction force normalized by the 186 
probe area. The results were expressed as the mean ± standard deviation of four determinations. 187 
 188 
Shear adhesion test – The shear adhesion test reveals the resistance of a PSA matrix to tangential 189 
stress and, therefore, the cohesion of the matrix of (trans)dermal patch. Briefly, specimens of 25 x 60 190 
mm were printed from each formulation (Table 1 and 2) and stored at 25 ± 1°C for two weeks to 191 
assure the stabilization of the adhesive matrix (Quaroni et al., 2018). The shear adhesion was 192 
performed using an 8 Bank Oven Shear HT8 Instrument (ChemInstruments, Ichemico, I) according 193 
to a method previously described using a 500 g mass to generate the stress. The experiments were 194 
performed at room temperature (25 ± 1 °C). The results were expressed as the mean ± standard 195 
deviation of four specimens. 196 
 197 
Peel adhesion 180° test – The peel adhesion reveals the resistance of (trans)dermal patch to peeling-198 
off. It has a crucial role in the characterization of (trans)dermal patch since high peel adhesion resulted 199 
in a more painful its removal from the skin by the patient. The tests were performed using a tensile 200 
machine equipped with a 50 N cell (Instron 5965, ITW Test and Measurement Italia S.r.l., I) using a 201 
Teflon® panel, accordingly to the method described by Cilurzo and co-workers (Cilurzo et al., 2008). 202 
(Trans)dermal patches printed with a 12 x 80 mm size were stored in primary packaging material at 203 
25 ± 1°C for two weeks before use. 204 
 205 
2.7 Drug content 206 
An accurately weighed 2.54 cm2 (trans)dermal patch was dissolved in 50 mL methanol by 207 
mechanically shaking and sonication (UP200st, Hielscher, D). Afterwards, the samples were left to 208 
rest overnight and, then, diluted 1:1 with mobile phase described below. Before the injection, samples 209 
were filtered with a 0.45 μm polypropylene filter (VWR International, I). The drug content in the 210 
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(trans)dermal patch was calculated as a function of both the matrix mass (μg/g) and area (μg/cm2). 211 
The results were expressed as the mean ± standard deviation of three specimens for each formulation. 212 
 213 
2.8 In vitro dissolution test 214 
The dissolution was performed by using an apparatus SR8 PLUS dissolution test station (Hanson 215 
Research, US) according to the disk assembly method described in the “Dissolution test for 216 
transdermal patches (01/2008:20904)” of European Pharmacopoeia. 217 
An 8.0 cm2 (trans)dermal patch was placed flat on the iron disk (mesh size of the disk net: 125 μm) 218 
with the adhesive surface facing up according to the method previously described. The vessels were 219 
filled with 300 mL of pH 7.4 PBS buffer, the water bath temperature was kept at 32.0 ± 0.5 °C, and 220 
the paddle speed was set at 25 rpm. At predetermined intervals (5, 10, 20, 30 min, 1, 2, 4, 6, 7, 24 h), 221 
5 mL samples were collected and immediately replenished with fresh medium. 222 
The solutions were assayed by HPLC, according to the methods reported below. The results were 223 
expressed as the mean ± standard deviation of three specimens for each formulation. The release rate 224 
constant was calculated according to Higuchi's equation as follows: 225 
𝑀𝑡 𝑀∞⁄ = 𝐾𝑡
0.5           (2) 226 
where Mt is the amount of drug released at time t, M∞ is the drug loading in the matrix and K is the 227 
release rate constant expressed as h-1. 228 
 229 
2.9 In vitro permeation studies 230 
The permeation studies were performed using abdominal skin from donors, who underwent cosmetic 231 
surgery. According to an internal protocol (Casiraghi et al., 2016), after removing the subcutaneous 232 
fatty tissue, the skin samples were immersed in water at 60 °C for 1 min, and the epidermis was 233 
carefully removed from the underlying tissue with the help of forceps. The integrity of epidermis 234 
samples was assessed measuring their electrical resistance (voltage: 100 mV, frequency: 100 Hz; 235 
Agilent 4263B LCR Meter, Microlease, I), using a modified Franz diffusion cell (PermeGear, US) 236 
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with an effective permeation area and a receptor volume of 0.636 cm2 and 3 mL, respectively. 237 
Samples with an electrical resistance higher than 20 kΩ·cm2 were used for the in vitro permeation 238 
experiments (Cilurzo et al., 2018).  239 
At the beginning of the in vitro permeation studies, a 2.5 cm2 circular sample, obtained from a printed 240 
(trans)dermal patch by a precision die cutter, was gently applied to the epidermis specimen. Then, the 241 
assembly was mounted on the receiver compartment of the Franz diffusion cell filled with saline 242 
solution, containing sodium azide (100 μg/mL), as a preservative, and maintained at 35 ± 1 °C, so 243 
that the skin surface temperature was 32 ± 1 °C. Special care was taken to avoid air bubbles between 244 
the epidermis and the medium in the receptor compartment. The receptor medium was continuously 245 
stirred with a small magnetic bar at 1800 rpm to assure a uniform distribution of the permeated drug. 246 
The upper and lower parts of the Franz diffusion cell were sealed with Teflon (VWR International, I) 247 
and Parafilm® (Pechiney Plastic Packaging Company, US) and fastened together using a clamp. At 248 
predetermined times (1, 3, 5, 7, 24 h), 200 μL samples were withdrawn from the receiver compartment 249 
and replaced with fresh receiver medium. Sink conditions were maintained throughout the 250 
experiments. Samples were analysed by HPLC according to the methods described below. The 251 
cumulative amount (Q) permeated through the skin per unit of area was calculated from the 252 
concentration of each substance in the receiving medium and plotted as a function of time. The steady 253 
flux (J) was calculated as the slope of the linear portion of the plot.  254 
 255 
2.10 HPLC method 256 
The drug content and the drug concentration in the dissolution medium were quantified by HPLC 257 
analysis (Agilent HP 1100, Chemstation, Hewlett Packard, US), using the following analytical 258 
methods. 259 
Ketoprofen – the following chromatographic conditions were used: column, HyperClone™ 5 μm 260 
BDS C18 130, 150x4.6 mm (Phenomenex, US); mobile phase, acetonitrile/water pH 2.6 (60/40, % 261 
v/v); flow rate, 1.5 mL/min; wavelengths, 225 nm; temperature, 25 °C; injection volume, 20μL. The 262 
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drug concentrations were determined from standard curves in the 0.1–50.0 μg/mL range (R2 = 263 
0.99999). 264 
Nicotine – the following chromatographic conditions were used: column, Lichropher 110RP-18E, 265 
125x4.0 mm, 5 μm (CPS Analitica, I) mobile phase, acetonitrile/KH2PO4 0.1M solution (25/75, % 266 
v/v) + 1.3 g/L sodium dodecyl sulphate; flow rate, 1.5 mL/min; wavelengths, 245 nm; temperature, 267 
30 °C; injection volume, 20 μL. The drug concentrations were determined from standard curves in 268 
the 0.1–50.0 μg/mL range (R2 = 0.99992). 269 
 270 
3 Results and Discussion 271 
 272 
3.1 Rheological pattern of designed formulations  273 
Rheological analyses show common trends according to the formulation tested: as expected, 274 
increasing the plasticizer ratio, the viscosity gets lower with both TBC and TRI. Fig. 1 shows the 275 
typical pattern of rheological analyses. As a general statement, EuRL formulations had higher 276 
viscosities in comparison to EuRS ones. This finding is probably due to a higher concentration of 277 
quaternary ammonium salt in EuRL, which increases ionic content and, consequently, the interactions 278 
with the polar groups of the plasticizer. A considerable difference between EuRL and EuRS is visible 279 
checking the crossover values, i.e. the frequency corresponding to the equivalence between loss (G’’) 280 
and storage (G’) modulus (Table 1). Accordingly, crossover occurs at higher frequencies when EuRS 281 
is used in comparison to the same formulations containing EuRL (Table 1), indicating that elastic 282 
modulus retains higher values for a higher range of frequencies. This different pattern confirmed the 283 
role of the percentages of ammonium groups present in the two copolymers. Interestingly, when using 284 
a 60/40 polymer/plasticizer ratio, a double crossover can be seen or expected, with the second 285 
crossover close to the highest frequency used for the analysis (100 rad/s). 286 
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The values of Tan δ (i.e. the G”/G’ ratio) minimum agree with the trends of G” vs G’, i.e. when EuRL 287 
and TBC are present, Tan δ minimum is visible at lower frequencies. When higher amounts of 288 
plasticizer are used, the minimum is out of the frequency range used for the analyses. 289 
 290 
3.2 Selection of the pressure-sensitive adhesive composition 291 
In agreement with the results of rheological analyses on polymeric blends, both the type of copolymer 292 
(i.e., EuRL or EuRS) and plasticizer (i.e., TBC or TRI) significantly impacted on the printability of 293 
the placebo (trans)dermal patches (Table 1). In particular, for EuRS, the use of both plasticizes in 294 
concentrations equal to 60% w/w resulted in too-fluid matrixes to be printable in a reproducible matter 295 
at the selected temperature. Moreover, the reduction of the extrusion temperature to 70°C resulted 296 
useless since the matrix flowed outside the edge of the (trans)dermal patch quickly after the 297 
application of the backing layer. EuRL showed a similar behaviour only when 60% w/w TRI was 298 
used. In the case of formulations designed with 40% w/w TBC the extrusion at 90°C led to a melt 299 
that was too stiff to adhere to the backing layer, so the temperature was increased up 100°C. These 300 
findings agreed with the complex viscosity (η*) of the polymeric blend at 25°C (1.5 Hz), even if such 301 
a temperature was significantly lower than extrusion one. The η*-values of EuRS-based (trans)dermal 302 
patches were lower than the equivalent EuRL formulations, justifying the worsening of the 303 
printability of (trans)dermal patch. Indeed, at equal plasticizer concentration, the EuRS matrices were 304 
more fluid than EuRL ones (Table 1). Moreover, TRI decreased more significantly the η*-value than 305 
TBC. These differences were more significant for EuRL-matrices (e.g., Form. 2 vs Form. 5) than 306 
EuRS ones (e.g., Form. 8 vs Form. 10). These results agreed with rheological results obtained on 307 
EuRL-based adhesive matrix prepared by solvent casting (Quaroni et al., 2018). Indeed, the 308 
rheological properties of EuRL/TRI-based matrices showed a more liquid-like behaviour than 309 
EuRL/TBC ones due to more significant interaction of TRI with polymeric chains.  310 
The overall results suggested that η*-values lower than 1 KPa/s were correlated to a high fluidity of 311 
the extruded materials to be printed in a defined shape and size, whereas values higher than 15 KPa/s 312 
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to melt matrices too stiff to adhere to the backing layer and to obtain homogenous (trans)dermal 313 
patches (Form. 1, Table 1). For η*-values ranged between 1 and 10 KPa/s, the formulations were 314 
printable in a reproducible matter.  315 
Starting from these results, the impact of the copolymer ratio was also tested using 50% w/w TBC or 316 
40% w/w TRI (Forms. 12-17, Table 1). In these cases, all the formulations showed η*-values in the 317 
range of printability of (trans)dermal patch, even if a slight decrease was observed increasing the 318 
EuRS concentration within the matrix. 319 
All the printed (trans)dermal patches resulted homogeneous (Fig. 2) with a reproducible thickness 320 
ranging 50 ± 10 μm. Nevertheless, several formulations showed a too high cold flow (Table 1). In 321 
particular, PSAs prepared with EuRL or EuRS with 60% w/w plasticizer failed the assay after one 322 
month of storage. This phenomenon occurs when, at low frequencies (in the range 0.05-0.5 rad/s), 323 
the G’ values are relatively low, and G” ones are predominant. In the case of printed (trans)dermal 324 
patches, the cold flow was observed when η*-value was lower than 3 kPa/s (at 1.5 Hz), and the ratio 325 
between G’ and tan δ determined at 0.4 rad/s was lower than 0.2 kPa (Rohn, 1959).  326 
Moving the attention to the adhesive properties, accordingly to Class and Chu, optimal tack properties 327 
of the prepared placebo (trans)dermal patches may be reached with the G’-values between 5 x 104 328 
and 2 x 105 Pa at frequencies between 0.005 and 0.05 rad/s (Rohn, 1959). In the case of printed 329 
(trans)dermal patches, the higher σmax and W-values were observed with G’-values around 103-104 330 
Pa, supporting the acceptable adhesive properties of the matrices. Moreover, the Dahlquist’s criterion 331 
(G’ ≤ 0.1 MPa at 1 Hz) was fulfilled by most of the formulations, suggesting that adhesive matrices 332 
were able to wet the adherend surface completely (Dahlquist, 1959). Indeed, exception made for 333 
Form. 1 which showed a weak adhesion property, all the formulations showed G’-values lower than 334 
105 Pa (Fig. 1). The G’-values of EuRS-based matrices (≤ 103 Pa) are significantly lower than those 335 
of EuRL ones; however, the higher Tan δ values revealed a higher viscous behaviour of the former 336 
matrices (G’’> G’) at low frequencies. In the case of EuRL matrices, when 40% w/w TRI was used 337 
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as a plasticizer, the tack parameters resulted significantly higher than those obtained from TBC-338 
containing matrices. However, this difference was significantly reduced, increasing the plasticizer 339 
concentration up to 50% w/w, due to a prevalence of the viscous behaviour of the materials (G’’> 340 
G’).  341 
EuRL matrices showed higher shear adhesion than EuRS matrices (e.g., Form. 1 vs Form. 7). This 342 
feature is in agreement with the rheological data showing a higher storage modulus (G’) in EuRL 343 
matrices than in EuRS, at frequencies between 0.05 and 0.5 rad/s that is the range usually considered 344 
to predict the shear adhesion (Fig. 1) (Rohn, 1959). 345 
The results of 180° peel adhesion tests demonstrated that the forces required to peel away all the 346 
printed (trans)dermal patches from the Teflon® surface were quite low. The type of plasticizer and 347 
copolymer composition did not influence peel value. This result could be due to the low critical 348 
surface tension of Teflon (Minghetti et al., 1999) which mimics the critical surface tension of the 349 
clean human skin and requires a low force for the detachment. On the other hand, the use of a substrate 350 
with a higher critical surface tension (i.e. steel) was tested but resulted not feasible since it caused an 351 
adhesive failure for several formulations (data not shown).  352 
However, it is noteworthy that the overall results of peel tests suggested that printed (trans)dermal 353 
patches were more easy-to-peel than styrene-based matrices prepared with other hot-melt extrusion 354 
techniques (Ma et al., 2013; Zhao et al., 2016).  355 
In the case of EuRL/EuRS blends, the tack (σmax and W-values, Table 1) was influenced by the EuRS 356 
concentration. In agreements with results obtained for EuRL and EuRS blends, the effects varied as 357 
a function of the plasticizer type. In the presence of TBC, the higher the EuRS concentration, the 358 
higher the σmax and W-values (Forms. 12-14, Table 1). On the contrary, the opposite trend was 359 
observed for TRI-based formulations (Forms. 15-17, Table 1). 360 
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The shear adhesion studies showed a low cohesivity of the TBC-contained matrices, whereas 361 
acceptable values were observed in the presence of TRI. Indeed, the shear adhesion of TRI-based 362 
(trans)dermal patches (>140 min) was 7-fold higher than TBC-based ones (< 20 min). Although the 363 
data of TRI series were lower than those obtained with other polymeric matrices prepared with hot-364 
melt extrusion techniques (Ma et al., 2013; Zhao et al., 2016), they agreed with those available in the 365 
literature for marketed loco-regional patches (Cilurzo et al., 2015), whereas are significantly higher 366 
than those obtained by nanofiber patches prepared by electrospinning (Shi et al., 2014). Moreover, a 367 
direct correlation between the matrix resistance to flow and the EuRL/EuRS ratio was found. Indeed, 368 
comparing matrices containing the same plasticizer, the higher the EuRL concentration, the higher 369 
the shear adhesion value (R2 = 0.87). This finding agreed with data published by Quaroni and co-370 
workers (Quaroni et al., 2018). The overall data confirms that the proposed preparation method does 371 
not affect the adhesive performances of the (trans)dermal patches in comparison to the consolidated 372 
solvent casting technique. 373 
 374 
3.3 Drug-loaded (trans)dermal patches 375 
Considering the pattern exhibited by placebo (trans)dermal patches, both KP and NT were loaded on 376 
adhesive matrixes starting from the placebo formulations prepared using the 40% w/w TRI (Table 377 
2).  378 
The loading of KP and NT did not affect the printing of the (trans)dermal patches, and they were 379 
reproducible enough to fulfil with the Ph Eur monograph on the uniformity of content (Table 3). 380 
Moreover, the PSA appears homogeneous without a sign of crystallization grown (Fig. 2). Neither 381 
for KP nor NT, no morphological differences were observed between the drug-loaded and placebo 382 
PSA. After the process, no significant degradation pattern of both KT and NT have been detected. 383 
Although a deepened characterization of the physical state of both drugs was not performed, the 384 
experimental data suggested no significantly variations were expectable based on previous evidence 385 
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reported on the literature obtained with PSA-matrixes made of the same PSA (Cilurzo et al., 2008; 386 
Quaroni et al., 2018). 387 
When both drugs were loaded in the adhesive matrices, the fluidity of the extruded material was 388 
increased, facilitating the printing of (trans)dermal patch. This evidence is also related to a reduction 389 
of the shear adhesion values in comparison to placebo printed (trans)dermal patches (Table 2). For 390 
examples, the shear adhesion value of Form. 16 (234 ± 45 min) decreased up to 3-fold and 9-fold 391 
when KP (Form. 16-KP: 64 ± 11 min) and NT (Form. 16-NT: 25 ± 5 min) was loaded in the matrix, 392 
respectively (p < 0.05, Student’s T-Test). However, the observed reduction should have no impact on 393 
the in vitro performances of the printed (trans)dermal patch onto patient skin since the observed 394 
values remained comparable to other marketed cutaneous patches and medicated plasters (Minghetti 395 
et al., 1999).  396 
The in vitro release studies demonstrated that the release profiles from EuRL/EuRS matrices 397 
depended on the type of loaded drug. Indeed, as shown in Fig. 3, the NT was released faster than KP 398 
from the same adhesive matrices. For example, 80% of NT was released in less than 30 min from 399 
Form. 4-NT, whereas KP in 4 hours from the same adhesive matrix (Form. 4-KP). This evidence was 400 
in line with published papers that had demonstrated the chemical interactions between KP and acrylic 401 
copolymer and their impact on the physicochemical features and the technological performance of 402 
the drug-loaded dosage form (Eerikäinen et al., 2004; Musazzi et al., 2018a; Rassu et al., 2008). 403 
Besides these results, it is noteworthy that the released rate constant of KP from Form. 4-KP (Table 404 
3) resulted slightly smaller but comparable to that obtained from a (trans)dermal patch with a similar 405 
composition but prepared by solvent casting technique [K = 0.78 ± 0.01 h-1 (Quaroni et al., 2018)]. 406 
These similarities in release profile suggested that, also for this property, the changes in preparation 407 
methods did not alter the ability of the matrix in released the loaded drug. Moreover, the in vitro drug 408 
release profiles also confirmed the role of copolymer ratio on the release of the drug through the 409 
matrices. It is noteworthy that EuRL matrix was more permeable to water and drugs than EuRS 410 
(Akhagari et al., 2006; Cilurzo et al., 2014a). The observed differences are also ascribable to a higher 411 
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swelling in aqueous solvents of EuRL compared to EuRS, especially around neutral pH (Akhagari et 412 
al., 2006). As shown in Table 3, the higher the EuRL concentration in the matrix, the higher the 413 
release rate constants. Indeed, regardless the loaded drug, the release rate constants increased in the 414 
following order: EuRL/EuRS 0/1 (Forms. 9-KP, 9-NT) < EuRL/EuRS 1/1 (Forms. 16-KP, 16-NT) 415 
< EuRL/EuRS 1/0 (Forms. 4-KP, 4-NT).  416 
These results agreed with literature regarding the influence of EuRL/EuRS ratio on the in vitro and 417 
in vivo performances of (trans)dermal patches (Aggarwal et al., 2013; Cilurzo et al., 2014a; Kusum 418 
Devi et al., 2003; Mutalik and Udupa, 2004). Indeed, according to the well-known characteristics of 419 
the two copolymers, the higher the concentration of EuRL in the matrix, the higher the permeability 420 
of the matrix and, therefore, the higher the release rate of drugs. This effect is independent of the 421 
physicochemical properties of the drug substance loaded in the matrix. Indeed, the addition of EuRS 422 
to the formulation of (trans)dermal patch altered the diffusion/release mechanism of the drug. In 423 
particular, 20% of EuRS can reduce the diffusion of verapamil significantly through a EuRL-based 424 
adhesive matrix (Kusum Devi et al., 2003). Mutalik and Udupa confirmed this trend (Mutalik and 425 
Udupa, 2004). From EuRL/EuRS-based transdermal patches, the drug release of glibenclamide, a 426 
well-known hypoglycemic drug, was reduced when the EuRS concentration increased from 25% to 427 
60% w/w.  428 
It is noteworthy that the differences observed in the in vitro release profiles are not relevant in terms 429 
of skin permeation of KP (Fig. 4). Indeed, even if the release rate constant of EuRL-based 430 
(trans)dermal patches (Form. 4-KP) resulted in more than two-time higher than EuRS-based 431 
(trans)dermal patches (Form. 9-KP), the permeation fluxes were superimposable (Table 3). Such 432 
results are comparable to those obtained by other medicated plasters, regardless of the matrix 433 
composition (Cilurzo et al., 2015; Quaroni et al., 2018) and agree with the general statement that the 434 
permeation process is mainly related to the drug thermodynamic activity in the formulation (EMA, 435 
2014). Indeed, the limiting step of drug permeation is the drug partition in the stratum corneum and 436 
not the drug release from the matrix. Therefore, the observed differences in the release rate of both 437 
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drugs may have a negligible impact on the actual concentration gradient between the outer and inner 438 
layers of the human epidermis, which is the real driving force of the permeation process. These 439 
considerations also justify the permeation pattern of NT (Fig. 4). In this case, the EuRS-based matrix 440 
permitted a high permeation (Form. 9-NT; Q24 = 387.12 ± 29.10) in comparison to EuRL-based 441 
matrix (Form. 4-NT; Q24 = 215.48 ± 38.56) in contrast with the dissolution data (Table 3). In 442 
agreement with the data discussed above, the decrease of the permeation flux of NT released by 443 
EuRL-based matrix observed after seven hours was attributed to a variation of the drug 444 
thermodynamic activity over time. The obtained results agreed with previously published data 445 
obtained from a similar polymeric matrix (Cilurzo et al., 2008).  446 
 447 
4 Conclusions 448 
The printing of hot-melt PSA based on poly-ammonium methacrylates, such as EuRL, EuRS and 449 
mixtures thereof, can be advantageously used for preparing or prototyping transdermal patches or 450 
medicated plasters. The selection of polymer/plasticizer ratio and the composition of other excipients 451 
can be easily optimized and controlled to guarantee suitable adhesive properties of the matrix and its 452 
stability during the time. Interestingly, the biopharmaceutical performances of the (trans)dermal patch 453 
(i.e., skin permeation) were not altered within the investigated formulative space, suggesting the high 454 
robustness of the proposed technology. Also, the obtained results evidenced that the performances of 455 
the printed (trans)dermal patches loaded with KP or NT are very close to that obtained by the 456 
conventional casting technique. Thus, the hot-melt ram extrusion printing can be a feasible 457 
technology in the production of very small batches for preliminary formulative studies, or 458 
preclinical/exploratory trials during the pharmaceutical development of a medicinal product. 459 
Moreover, it could be useful in the compounding of personalized cutaneous patches when the 460 
treatment of skin diseases requires original patch shape.  461 
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In conclusion, printing technologies can be advantageously used to produce small batches of 462 
(trans)dermal patches even if they require PSA appositely designed. As in the example reported in 463 
the actual study, the use of a hot-melt printing technique requires a material which exhibits a suitable 464 
viscosity to be printed at relatively lower temperatures than those generally required by a hot-melt 465 
extrusion process (Thakkara et al. 2020), and acquires suitable viscoelastic performances at room 466 
temperature to avoid cold flow and show acceptable adhesive properties. Starting from this proof-of-467 
concept, further studies are required to better investigate the impact of the printing on the chemical 468 
and physical state of drug substances loaded in the (trans)dermal patches. 469 
  470 
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Figures 471 
 472 
Fig. 1 Evolution of G’ (solid line), G’’ (long-dashed line) and Tan δ (dotted line) as a function of 473 
frequency. (A) EuRL patch formulations containing TRI and (C) TBC; (B) EuRS patch formulations 474 
containing TRI and (D) TBC. Black line: formulations containing 40% w/w of plasticizer, grey line: 475 
formulations containing 50% w/w of plasticizer and light grey line: formulations containing 40% w/w 476 
of plasticizer. Tests were performed at 25°C. 477 
 478 
Fig. 2 Printed (trans)dermal patch during peeling off from the release liner (PSA: pressure-sensitive 479 
adhesive matrix; BL: backing layer; RL: release liner) (A) and microscopic image of KP-loaded 480 
patches (Form 4-KP), adhesive matrix plus backing layer, after removal of release liner (B). The 481 
image was taken on printed patched stored at room temperature for six months. No signs of 482 
crystallization were observable. The black spots detectable in the background belong to the intrinsic 483 
opacity of backing layer.  484 
 485 
Fig. 3 In vitro release profiles of KP- (A) and NT-loaded patches (B) (Mean ± St.Dev.; n =3). Solid 486 
squares and lines: Forms 4-KP and 4-NT; Solid rhombus and dashed lines: Forms. 16-KP and 16-487 
NT; Solid circles and dotted lines: Forms. 9-KP and 9-NT. 488 
 489 
Fig. 4 In vitro permeation profiles of KP- (A) and NT-loaded patches (B) (Mean ± St.Dev.; n =3). 490 
Solid squares and lines: Forms 4-KP and 4-NT; Solid circles and dotted lines: Forms. 9-KP and 9-491 
NT. 492 
   493 
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Table 1 Composition (%) of placebo patches used for screening the acceptable polymer/plasticizer ratio in terms of matrix printability, cold flow after 
one month of storage, rheological and adhesive properties. The matrix printability is expressed by the following score system: A (easily printable), B 
(printable not in a reproducible way), and C (not printable). For cold flow: N, the absence of cold flow; Y, the presence of cold flow. 
Form 
Composition (%) 
Printability 
Rheological properties Adhesive properties 
EuRL EuRS TBC TRI 
Cold 
flow1 
η* (kPa/s)2 
Cross over 
(rad/s) 
Tack  Shear adhesion 
(min) 
Peel adhesion 
(cN/cm) σmax (kPa) W (mJ) 
1 60 - 40 - B N 20.5 0.1 5.9±1.5 0.008±0.001 2062±1124 12.8±5.1 
2 50 - 50 - A N 6.1 0.4 246.8±61.2 0.105±0.023 157±43 15.2±2.1 
3 40 - 60 - A Y 1.6 2.2 -3 -3 -3 -3 
4 60 - - 40 A N 11.5 0.2 218.0±17.0 0.053±0.013 396±79 12.5±0.5 
5 50 - - 50 B N 4.0 2.5 252.5±49.7 0.065±0.038 170±20 3.5±2.4 
6 40 - - 60 C Y 1.0 13.5 -3 -3 -3 -3 
7 - 60 40 - A N 10.9 1.0; 17.6 292.2±43.3 0.193±0.060 553±385 50.3±19.5 
8 - 50 50 - B Y 2.4 >100 -3 -3 -3 -3 
9 - 60 - 40 B N 7.6 3.4 125.2±85.3 0.093±0.059 181±10 14.2±2.9 
10 - 50 - 50 B Y 2.0 40.0 -3 -3 -3 -3 
11 - 40 - 60 C Y 0.5 > 100 -3 -3 -3 -3 
12 37.5 12.5 50 - A N 4.2 25.0 167.1±35.7 0.068±0.025 17 ± 4 12.8±7.9 
13 25 25 50 - A N 5.6 > 100 114.2±24.7 0.067±0.017 5±1 7.4±0.9 
14 12.5 37.5 50 - B N 2.9 > 100 7.5±5.4 0.022±0.012 8±1 7.4±0.5 
15 45 15 - 40 A N 10.1 0.9 8.5±0.9 0.006±0.001 364±149 7.4±1.1 
16 30 30 - 40 A N 7.3 2.5 87.6±32.2 0.046±0.016 234±45 10.3±1.0 
17 15 45 - 40 B N 4.6 44.0 214.5±49.3 0.093±0.016 149±41 15.3±0.7 
1 40°C, 1 month; 2 determined at 1.5 Hz; 3 not determined since the cold flow was observed 
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Table 2 Composition (%) of drug-loaded patches, thickness, and their characterization in term of cold flow after one month at 25°C or at 40°C, and 
adhesive properties (N: the absence of cold flow; Y: the presence of cold flow). 
Form. 
Composition (%) 
Thickness 
(μm) 
Cold flow Adhesive properties 
EuRL EuRS TBC TRI KP NT 25°C 40°C 
Shear adhesion 
(min) 
Peel adhesion 
(cN/cm) 
4-KP 58.60 - - 39.06 2.34 - 54 ± 8 N Y 66 ± 3 7.7 ± 0.4 
9-KP - 58.60 - 39.06 2.34 - 58± 14 N Y 67 ± 3 14.9 ± 5.8 
16-KP 29.30 29.30 - 39.06 2.34 - 59 ± 11 N Y 64 ± 11 13.5 ± 1.3 
4-NT 58.20 - - 39.06 - 3.00 62 ± 13 N N 81 ± 3 5.3 ± 0.4 
9-NT - 58.20 - 39.06 - 3.00 67± 9 N N 21 ± 8 12.0 ± 0.7 
16-NT 29.10 29.10 - 39.06 - 3.00 66 ± 16 N N 25 ± 5 9.4 ± 0.8 
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Table 3 Drug content, release rate constant (K) and skin permeation flux (J) of printed drug-loaded patches (Mean ± St.Dev.; n = 3; n.d.: not determined). 
Form. Drug 
Drug content K 
(h-0.5) 
J 
(μg/cm2/h) μg/mg μg/cm2 
4-KP KP 2.2 ± 0.1 166.1 ± 8.3 0.41 ± 0.02 0.60 ± 0.02 
9-KP KP 2.3 ± 0.0 152.1 ± 29.4 0.13 ± 0.01 0.60 ± 0.13 
16-KP KP 2.3 ± 0.1 161.7 ± 15.8 0.15 ± 0.01 n.d. 
4-NT NT 2.3 ± 0.1 158.6 ± 35.1 2.61 ± 0.05 15.28 ± 3.07 
9-NT NT 3.0 ± 0.5 196.6 ± 12.2 0.29 ± 0.07 20.38 ± 3.13 
16-NT NT 2.2 ± 0.4 136.5 ± 13.7 1.36 ± 0.09 n.d. 
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